Clinical Trials Logo
  1. Home
  2. Nash
  3. NCT03187496

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NASH Clinical Trial

Official title:
A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-305 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Human Volunteers

Clinical Trial Summary

A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human volunteers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03187496
Study type Interventional
Source Enanta Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date May 11, 2017
Completion date June 14, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05479721 - LITMUS Imaging Study
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02923154 - Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) Phase 2
Withdrawn NCT03980912 - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
Terminated NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Phase 1
Not yet recruiting NCT05935488 - Early Liver Disease Breath Detection
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT05327127 - Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis Phase 2
Completed NCT06348706 - Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes Phase 3
Active, not recruiting NCT06315361 - DIAbetes and NAFLD
Not yet recruiting NCT06364462 - Precise Evaluation Criteria for Histological Regression of NASH Fibrosis
Recruiting NCT04442334 - The European NAFLD Registry
Recruiting NCT06338969 - The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis N/A
Recruiting NCT05193916 - A Phase II Clinical Trial of Chiglitazar for NASH Phase 2
Active, not recruiting NCT05669677 - Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Not yet recruiting NCT04783116 - Plant Stanols and Liver Inflammation in Overweight and Obese Children N/A
Recruiting NCT06193629 - A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar N/A
Completed NCT04006145 - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Phase 2
Recruiting NCT04232293 - Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT04925362 - THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) N/A